Infectious Diseases

Weill Cornell Medicine has been awarded a five-year, $5 million grant from the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to establish a new multi-institutional center for tuberculosis (TB) research and training the next generation of TB investigators.

Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy.

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine physician-scientists who performed the transplant and managed her care.

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs.

Omicron — the latest coronavirus variant to be labeled a “variant of concern” — has been spreading rapidly in the United States and dozens of countries around the world.

Convalescent plasma did not reduce the risk of intubation or death for hospitalized COVID-19 patients in a large, international clinical trial conducted by Weill Cornell Medicine and NewYork-Presbyterian investigators in collaboration with lead investigators at McMaster University.

Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.

The spread of the Delta variant has put countries around the world on high alert. Dr. Roy M. Gulick, chief of the Division of Infectious Diseases at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and professor of medicine at Weill Cornell Medicine, answers questions about the new threat.

A team led by researchers at Weill Cornell Medicine and Children’s National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.

Using an antibody to block HIV from infecting cells may be an effective and more convenient way to prevent acquisition of HIV, suggests a preliminary study by a multi-institution team of researchers led by investigators from Weill Cornell Medicine and Oregon Health and Science University (OHSU).

Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.

Severe COVID-19 involves a distinctive reprogramming of gene activity in infected patients‘ immune cells, according to a study led by researchers at Weill Cornell Medicine.

A new test for measuring the reservoir of HIV hidden in the cells of people with HIV failed to detect this reservoir in a significant number of people with a subtype of HIV-1, according to a study from scientists at Weill Cornell Medicine, Simon Fraser University and the British Columbia Centre for Excellence in HIV/AIDS.

When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.

With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.

Dr. Kyu Rhee, an associate professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine, has been awarded a Physician-Scientist Institutional Award by the Burroughs Wellcome Fund.

Physicians, researchers and policymakers around the globe are grappling with the rise of antibiotic-resistant bacteria—a threat with the potential to derail decades of medical advances.